✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Medication Reference

Compounded Tirzepatide

Released: Last reviewed:

Complete reference page for compounded tirzepatide in 2026: 503A vs 503B pathway, base vs salt-form distinction, pricing across telehealth providers, traceability standards, and clinical context.

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

What is compounded tirzepatide?

Compounded tirzepatide is a preparation of the tirzepatide molecule made by a state-licensed 503A compounding pharmacy; it is not FDA-approved. It is dispensed against a patient-specific prescription (503A). In April 2026 FDA proposed not to add tirzepatide to the 503B bulks list; no final decision had been published as of November 20, 2026. It is not FDA-approved and is not the same product as Mounjaro® (FDA-approved for type 2 diabetes) or Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea), both manufactured by Eli Lilly.

Base vs salt forms (regulatory line)

The active pharmaceutical ingredient must be tirzepatide base. The FDA has issued warning letters specifically against compounded tirzepatide preparations using salt forms (tirzepatide acetate, tirzepatide sodium), citing that these are not pharmacologically equivalent to the base molecule. A legitimate compounded tirzepatide provider should be able to produce a certificate of analysis showing the active ingredient is tirzepatide base.

The 503A vs 503B pathway

Read the full 503A vs 503B explainer →

Provider pricing comparison (May 2026)

ProviderMonthlyNotes
NexLife (highest v4.1 score)$115/mo (12-mo plan)Flat across 2.5–15 mg titration. Medical guidance from NexLife Medical Group; three 503A pharmacies named on its plan pages (two in its FAQ).
Mochi HealthFrom $90 at the starting dose, plus a $49–$79 monthly membershipPriced by dose; higher doses not printed (joinmochi.com, read November 20, 2026).
Hims compounded$249–$349/mo (May 2026 figure; not re-read)Not re-read: hims.com returned HTTP 403 on November 20, 2026.
Henry MedsNo injectable tirzepatide price printedIts price list (dated December 3, 2025) shows only an oral tirzepatide 3-month supply (henrymeds.com, read November 20, 2026).

Quality assurance documentation to ask for

Clinical context

Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist. SURMOUNT-1 (NEJM 2022, PMID 35658024) demonstrated 20.9% mean weight loss at 15 mg / 72 weeks. SURMOUNT-OSA (NEJM 2024) demonstrated apnea-hypopnea index reduction in obesity-related OSA. The boxed warning is for thyroid C-cell tumors; contraindicated in personal/family history of MTC or MEN-2.

Related pages